Diagnostic value of miRNA-101 and miRNA-27 in acute heart transplant rejection
https://doi.org/10.15825/1995-1191-2020-4-20-26
Abstract
Objective: to determine the diagnostic value of miRNA-101 and miRNA-27 expression levels for acute heart
transplant rejection.
Materials and methods. The study enrolled 46 heart recipients, among whom were 36 men (78.3%); the average age of recipients was 47.7 = 10.8 (16 to 67) years. Serum microRNA expression levels were measured via quantitative polymerase chain reaction (PCR). Graft rejection was verified through morphological analysis of endomyocardial biopsy specimens.
Results. The expression levels of miRNA-101 and miRNA-27 in recipients with acute graft rejection are significantly lower than in recipients without rejection (p = 0.04 and p = 0.03, respectively). When the miRNA-101 expression level is below the determined threshold value, the risk of developing acute graft rejection increases 1.8 times (RR = 1.8 [95% CI 1.13–3.01]). When the miRNA-27 expression level is below the determined threshold value, the risk of developing acute graft rejection increases 1.9 times (RR = 1.9 [95% CI 1.12–3.37]). Simultaneous decrease in the expression levels of miRNA-101 and miRNA-27 below the determined threshold values increases the likelihood of acute graft rejection by 2.0 times (RR = 2.0 [95% CI 1.16–3.36]).
Conclusion. The serum miRNA-101 and miRNA-27 expression levels are of diagnostic value for acute graft rejection in heart recipients.
About the Authors
D. A. Velikiy
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
1, Shchukinskaya str., Moscow, 123182, Russian Federation
Phone: (499) 193-87-62
O. E. Gichkun
Shumakov National Medical Research Center of Transplantology and Artificial Organs;
Sechenov University
Russian Federation
Moscow
Russian Federation
Moscow
S. O. Sharapchenko
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation
Moscow
Russian Federation
Moscow
N. P. Mozheiko
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation
Moscow
Russian Federation
Moscow
R. M. Kurabekova
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation
Moscow
Russian Federation
Moscow
O. P. Shevchenko
Shumakov National Medical Research Center of Transplantology and Artificial Organs;
Sechenov University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem: rukovodstvo dlya vrachej po vedeniyu pacientov, perenesshih transplantaciyu serdca. M.: Triada, 2014. 144.
2. Shevchenko AO, Nikitina EA, Koloskova NN, Shevchenko OP, Gautier SV. Kontroliruemaja arterial’naja gipertenzija i vyzhivaemost’ bez nezhelatel’nyh sobytij u recipientov serdca. Kardiovaskuljarnaja terapija i profilaktika. 2018; 17 (4): 4–11. [In Russ, English abstract].
3. Stehlik J, Starling RC, Movsesian MA, Fang JC, Brown RN, Hess ML et al. Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006; 25 (12): 1402–1409.
4. Crespo-Leiro MG, Barge-Caballero G, Couto-Mallon D. Noninvasive monitoring of acute and chronic rejection in heart transplantation. Curr Opin Cardiol. 2017; 32 (3): 308–315.
5. Shumakov VI, Shevchenko OP, Hubutiya MSh, Orlova OV, Kazakov EN, Kormer AYa, Olefirenko GA. Vaskulopatiya transplantirovannogo serdca: sinergizm provospalitel’nyh, proaterogennyh faktorov i virusnoj infekcii. Vestnik Rossijskoj akademii medicinskih nauk. 2006; 11: 8–14.
6. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel biomarkers of heart failure. Advances In Clinical Chemistry. 2017; 79: 93–152.
7. Kransdorf EP, Kobashigawa JA. Novel molecular approaches to the detection of heart transplant rejection. Per Med. 2017 Jul; 14 (4): 293–297.
8. van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol. 2017 Dec; 83 (12): 2602–2604.
9. Starling RC, Stehlik J, Baran DA et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation-05 study. American Journal of Transplantation. 2016; 16: 121–136.
10. Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. J Heart Lung Transplant. 2018 Nov; 37 (11): 1329–1340.
11. Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 Dec; 14 (6): 454–464.
12. Khush K, Zarafshar S. Molecular Diagnostic Testing in Cardiac Transplantation. Curr Cardiol Rep. 2017 Oct 13; 19 (11): 118.
13. Velikiy DA, Gichkun OE, Sharapchenko SO, Shevchenko OP, Shevchenko AO. Uroven’ ekspressii mikroRNK v rannie i otdalennye sroki posle transplantacii u recipientov serdca. Vestnik transplantologii i iskusstvennyh organov. 2020; 22 (1): 26–34.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec; 25 (4): 402–408.
15. Li X, Zhang S, Wa M, Liu Z, Hu S. microRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1. J Am Heart Assoc. 2019 Dec 3; 8 (23): e013112.
16. Huang C, Xiao X, Yang Y, Mishra A, Liang Y, Zeng X et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J Biol Chem. 2017 Oct 6; 292 (40): 16420–16439.
17. Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P. Mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients. 2019 Oct 29; 11 (11): 2597.
18. Zhang XL, An BF, Zhang GC. MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-κB pathway. Kaohsiung J Med Sci. 2019 Oct; 35 (10): 607–614.
19. Wang Y, Cai H, Li H, Gao Z, Song K. Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum Cell. 2018 Jul; 31 (3): 251–260.
20. Hughes G. Youden’s Index and the Weight of Evidence Revisited. Methods Inf Med. 2015; 54 (6): 576–577.
Review
For citations:
Velikiy D.A., Gichkun O.E., Sharapchenko S.O., Mozheiko N.P., Kurabekova R.M., Shevchenko O.P. Diagnostic value of miRNA-101 and miRNA-27 in acute heart transplant rejection. Russian Journal of Transplantology and Artificial Organs. 2020;22(4):20-26. https://doi.org/10.15825/1995-1191-2020-4-20-26
Views:
639
Email this article 